Pilot Study to Assess the Safety, PK and Iron Chelating Activity of DST-0509 (Deferasirox) in Thalassemia Patients Refractory to Chelation

NCT03637556 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

25

Enrollment

INDUSTRY

Sponsor class

Conditions

Thalassemia Major

Interventions

DRUG: DST-0509
DRUG: Jadenu
DRUG: Exjade

Sponsor

DisperSol Technologies, LLC